Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: The Small-Cap Rotation Continues

    In this Economics Weekly, Richard de Chazal discusses why we maintain our view that we are in a small-cap stock cycle, and why investors should once again shift their gaze in this direction.

    Read more

  • William Blair Initiates Coverage of Three Oil and Gas Companies

    William Blair initiated research coverage of Chevron Corporation (CVX $228.23), ConocoPhillips (COP $147.96), and ExxonMobil Holdings Corporation (XOM $179.91), three leading global oil and gas companies.

    Read more

  • Monthly Macro: Midterms, Markets, and What Comes Next

    William Blair macro analyst Richard de Chazal looks beyond the political headlines to examine what the midterm elections could mean for policy, interest rates, and markets, and where the results could matter most for investors.

    Listen to the podcast
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures